转自：新华财经 《"健康中国2030"规划纲要》提出，实现国民健康长寿，是国家富强、民族振兴的重要标志。日前， 以"跨越发展 引领未来"为主题，聚焦国产药高质量发展的调研行与专题研讨会在山东济南举办，汇集 行业力量，共探医药创新之路。 近年来，以齐鲁制药为代表的药企秉持着"大医精诚、家国天下"的情怀，为助推中国医药产业高质量发 展提供了强劲动能。作为国家集采的代表性产品之一，美达信®于2019年12月被纳入国家药品集中采购 目录。目前，美达信®已惠及超过1亿中国心血管疾病患者人群，不仅实现了大规模进口替代，极大减 轻了患者的用药经济负担，成为民族药企积极参与集采、实现国产替代的典型代表之一。 截至今年11月，齐鲁制药共有109个产品中标及续约，30个集采药品同步出口至33个国家和地区，让越 来越多有用药需求的患者用上了"齐鲁好药"。 健康中国，需要高水平创新战略支撑。在国产药高质量发展专题研讨会上，多位专家学者、企业代表围 绕"在迈向制药强国的路上，如何讲好国产药高质量发展的故事"等议题展开讨论，探索中国医药产业高 质量发展新方向。 其中，关于齐鲁制药科研成果的一串数字让人印象深刻：近300项品牌非专利药在研 ...

在"健康中国"战略深入推进、医药产业向创新转型的关键期，国产药企正以科技创新破解"卡脖子"难题，推动中国从医药大国 向医药强国跨越。 近日，"国产药高质量发展调研行暨专题研讨会"在济南举办，行业专家、学者及企业代表齐聚齐鲁制药，围绕创新药研发、仿 制药提质、产业生态构建等核心议题展开深度探讨。作为深耕医药领域40余年的民族药企标杆，齐鲁制药以"创仿并重"战略为 核心，凭借全球化研发体系与产能布局，在抗肿瘤、抗感染、自身免疫性疾病等关键治疗领域持续突破，为"十五五"期间国产 药高质量发展提供了实践样本。 政策产业双轮驱动，国产药进入高质量发展深水区 近年来，医药行业政策密集落地，从药品审评审批制度改革到带量采购常态化，从创新药医保准入到知识产权保护强化，政策 体系持续完善，推动行业从"规模扩张"向"质量提升"转型。 在仿制药领域，齐鲁制药以"质量等同、疗效一致"为核心，率先通过仿制药一致性评价，累计有219余个品种通过一致性评价， 其中68个品种为国内首家获批。公司通过技术攻关，突破了多项仿制药生产的关键技术壁垒，在抗生素、降压药、降糖药等大 众用药领域，实现了与原研药的质量和疗效一致，大幅降低了患者用药成本。 ...

Core Insights - The article highlights the transformation of China's pharmaceutical industry from a "big pharmaceutical country" to a "strong pharmaceutical country," emphasizing the importance of high-quality development and innovation in the sector [2][3] Group 1: Event Overview - The "High-Quality Development Research Tour of Domestic Medicines" was successfully held in Jinan, Shandong, from June 4 to June 6, 2025, organized by the China Pharmaceutical News Information Association and Beijing Daily Client [1] - The event involved over 20 major media outlets, focusing on the research and innovation platform, quality management system, and intelligent production base of Qilu Pharmaceutical [1] Group 2: Qilu Pharmaceutical's Achievements - Qilu Pharmaceutical has won 7 National Science and Technology Progress Awards and has 208 products listed in the National Medical Insurance Directory as of June 2025 [2] - The company has achieved leadership in the industry in terms of consistency evaluation, first-time evaluations, and national procurement bidding [2] - Qilu's R&D investment has increased from 5%-8% of sales revenue to 10%-12%, with an expected cumulative investment exceeding 20 billion yuan during the 14th Five-Year Plan period [3] Group 3: International Expansion - Qilu Pharmaceutical is the only domestic company exporting formulations to major regulatory markets including Europe, the US, Japan, Australia, and Canada, with 38 products holding the top market share in their respective regions [4] - The company's export revenue reached 1.02 billion USD in 2024 [4] Group 4: Technological Innovations - Qilu has developed groundbreaking technologies such as dual-function combination antibody preparation technology and large-scale cell culture technology, establishing an internationally leading MabPair combination antibody technology platform [6] - The company has implemented fully automated production lines, ensuring quality consistency and traceability throughout the production process [5] Group 5: Industry Dialogue - A seminar titled "Quality Leads, Good Medicines Accessible" was held during the research tour, where experts discussed the need for improved public perception of domestic medicines and the importance of collaborative efforts among media, academia, and regulatory bodies [6] - Qilu has 15 products among those selected in national procurement that rank highly in the US market [6] Group 6: Future Directions - The "High-Quality Development Research Tour of Domestic Medicines" will continue to focus on the pharmaceutical industry, expanding research to more domestic pharmaceutical companies across the country [7]

Core Insights - The event "High-Quality Development of Domestic Pharmaceuticals" was held at Qilu Pharmaceutical Group, aimed at showcasing the true quality of domestic drugs and the achievements of China's manufacturing industry [1][3] - A seminar was conducted where industry experts and media representatives discussed the challenges and opportunities in the high-quality development of domestic pharmaceuticals [3][5] Group 1: Industry Overview - The event was organized by the China Pharmaceutical News Information Association, focusing on quality management systems, R&D innovation platforms, and intelligent manufacturing bases [1] - Experts emphasized the need for strong promotion and scientific communication to enhance the brand image of domestic pharmaceuticals, highlighting their quality, international standing, and contributions to public health [3] Group 2: Company Insights - Qilu Pharmaceutical, as a leading domestic pharmaceutical company, shared its experiences in innovation, smart manufacturing, and international quality system construction [3][5] - The company has over 300 products on the market, with more than 70 being the first or exclusive in China, significantly reducing the economic burden on the national healthcare system [7][9] Group 3: R&D and Innovation - Qilu Pharmaceutical is actively developing over 80 innovative drug projects, with two national class I new drugs already launched [9] - The company has established six R&D centers in the U.S. and is focused on high-end new formulations, achieving breakthroughs in various advanced drug delivery systems [9] Group 4: Market Position and Strategy - Qilu Pharmaceutical has a leading market share in domestic clinical prescriptions and is expanding its presence in international markets, with nearly 40 formulation products in regions like the U.S., EU, Japan, and Australia [7][9] - The company has won bids for 100 drugs under the national drug procurement policy, significantly lowering drug prices to benefit the public [9]